Lanka to finalise agreement to secure Covid-19 vaccine through Covax

Sri Lanka is all set to finalise an agreement to secure Covid-19 vaccine via the United Nations-backed Covax facility

vaccine, Covid vaccine, Pfizer vaccine
Representational image of a Covid-19 vaccine
Press Trust of India Colombo
2 min read Last Updated : Jan 05 2021 | 5:57 PM IST

Sri Lanka is all set to finalise an agreement to secure COVID-19 vaccine via the United Nations-backed COVAX facility, which subsidises the shots for 92 low and middle income countries.

The COVAX or COVID-19 Vaccine Global Access programme is run by Gavi, the Vaccine Alliance, and the World Health Organisation (WHO) in partnership with developed and developing country vaccine manufacturers.

Sri Lanka joined the COVAX facility last year and the Global Alliance for Vaccines and Immunisation (GAVI) has accredited the nation, making it eligible to receive the vaccines through the programme.

The Lanka Cabinet will sign part two of the COVAX agreement with the WHO this week, enabling the country to obtain a limited quantity of the COVID-19 vaccine in the first quarter of this year, according to an official statement.

The signing of the second part has to be done by January 8, it said.

Eligible countries are required to submit request applications under two phases to receive the vaccine facility.

The first part -- which include information regarding the target group, storage capacity and technical information -- was required to be submitted before December 7 and Lanka has done it on time, the statement said.

The Lankan government had earlier said that it would also opt for the coronavirus vaccine developed by Russia.

There has been a surge in COVID-19 infections in Lanka since early October. The number of deaths which stood at just 13 till October has now passed the 200-mark. The total cases exceed 45,240.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirussri lankaCoronavirus Vaccine

First Published: Jan 05 2021 | 5:52 PM IST

Next Story